IVVD Doubled on Clinical Trial Results
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. Earnings in 48 days. Avg 30D Vol at 24.67M Current Vol at 74.70M
Can this break and retest $2.35? If it does analyst have targets as high as $10. GL!
Can this break and retest $2.35? If it does analyst have targets as high as $10. GL!
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.